Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

About Rigel Pharmaceuticals

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RIGL
  • CUSIP: 76655960
Key Metrics:
  • Previous Close: $2.32
  • 50 Day Moving Average: $2.30
  • 200 Day Moving Average: $2.81
  • 52-Week Range: $1.88 - $4.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.48
  • P/E Growth: -0.05
  • Market Cap: $227.56M
  • Outstanding Shares: 98,937,000
  • Beta: 1.24
Profitability:
  • Net Margins: -255.84%
  • Return on Equity: -86.54%
  • Return on Assets: -61.98%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 4.19%
  • Quick Ratio: 4.19%
Additional Links:
Companies Related to Rigel Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Rigel Pharmaceuticals (NASDAQ:RIGL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.20 (169.57% upside)

Analysts' Ratings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Show:
DateFirmActionRatingPrice TargetDetails
1/30/2017BMO Capital MarketsReiterated RatingOutperform$4.00View Rating Details
1/11/2017Jefferies Group LLCReiterated RatingBuy$5.00View Rating Details
11/2/2016HC WainwrightReiterated RatingBuyView Rating Details
11/2/2016Piper Jaffray CompaniesSet Price TargetBuy$11.00View Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingBuy$5.00View Rating Details
4/23/2016Credit Suisse GroupUpgradeBuyView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)ViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.17)($0.17)($0.17)
Q2 20161($0.18)($0.18)($0.18)
Q3 20161($0.17)($0.17)($0.17)
Q4 20161($0.14)($0.14)($0.14)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Ownership Percentage: 7.07%
Institutional Ownership Percentage: 72.23%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Rigel Pharmaceuticals (NASDAQ:RIGL)
DateHeadline
realistinvestor.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EPS Projection At $-0.02 - RealistInvestor.com (NASDAQ:RIGL)
www.realistinvestor.com - February 26 at 11:44 AM
marketexclusive.com logoRIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:RIGL)
marketexclusive.com - February 26 at 11:44 AM
News IconChecking the Numbers on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - BVN (NASDAQ:RIGL)
bvnewsjournal.com - February 24 at 8:07 AM
News IconInvestor Monitor: Narrowing in on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Midway Monitor (NASDAQ:RIGL)
midwaymonitor.com - February 23 at 8:26 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Aiken Advocate (NASDAQ:RIGL)
aikenadvocate.com - February 21 at 5:19 PM
News IconInvesting Focus: Indicators in View on Shares of Rigel Pharmaceuticals Inc. (RIGL) - Rives Journal (NASDAQ:RIGL)
rivesjournal.com - February 14 at 5:38 AM
News IconMarket Focus: Checking Up on Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Benton Bulletin (NASDAQ:RIGL)
bentonbulletin.com - February 11 at 3:48 AM
biz.yahoo.com logoRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh (NASDAQ:RIGL)
biz.yahoo.com - February 8 at 11:10 PM
News IconShould You Buy PDL BioPharma, Inc. (NASDAQ:PDLI) On Current Analyst Views? (NASDAQ:RIGL)
mundoaguaysaneamiento.net - February 7 at 11:17 PM
finance.yahoo.com logoRigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares (NASDAQ:RIGL)
finance.yahoo.com - February 3 at 10:57 PM
streetinsider.com logoRigel Pharma (RIGL) Prices 20M Common Stock Offering at $2/Share - StreetInsider.com (NASDAQ:RIGL)
www.streetinsider.com - February 1 at 11:27 PM
4-traders.com logoRigel Pharmaceuticals : Announces Pricing Of Public Offering Of Common Stock (NASDAQ:RIGL)
www.4-traders.com - January 31 at 9:56 PM
us.rd.yahoo.com logoRigel Announces Pricing Of Public Offering Of Common Stock (NASDAQ:RIGL)
us.rd.yahoo.com - January 31 at 9:56 PM
4-traders.com logoRigel Pharmaceuticals : Announces Proposed Public Offering Of Common Stock (NASDAQ:RIGL)
www.4-traders.com - January 31 at 1:16 AM
streetinsider.com logoRigel Pharma (RIGL) Plans Offering of Common Stock (NASDAQ:RIGL)
www.streetinsider.com - January 30 at 8:15 PM
us.rd.yahoo.com logoFostamatinib Study Results Continue to Trend Positive (NASDAQ:RIGL)
us.rd.yahoo.com - January 30 at 8:15 PM
us.rd.yahoo.com logo7:31 am Rigel Pharma announces updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura; Rigel believes the data further validates fostamatinib as a potential new treatment option for some p (NASDAQ:RIGL)
us.rd.yahoo.com - January 30 at 8:15 PM
finance.yahoo.com logoRigel Announces Proposed Public Offering Of Common Stock (NASDAQ:RIGL)
finance.yahoo.com - January 30 at 8:15 PM
News IconWhy the Rigel Pharmaceuticals Update Could Signal Further Growth (NASDAQ:RIGL)
feedproxy.google.com - January 30 at 2:10 PM
finance.yahoo.com logoFostamatinib Study Results Continue to Trend Positive - Yahoo Finance (NASDAQ:RIGL)
finance.yahoo.com - January 30 at 8:01 AM
News IconStock Watch for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Gilbert Daily (NASDAQ:RIGL)
gilbertdaily.com - January 30 at 8:01 AM
prnewswire.com logoGeneric Drugs Stocks on Investors' Radar -- Ironwood Pharma, Medicines, Rigel Pharma, and Lannett - PR Newswire (press release) (NASDAQ:RIGL)
www.prnewswire.com - January 30 at 8:01 AM
News IconStock Backsliding Ahead of the Bell: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Aiken Advocate (NASDAQ:RIGL)
aikenadvocate.com - January 24 at 8:09 AM
News IconLooking Ahead for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:RIGL)
aikenadvocate.com - January 24 at 8:09 AM
News IconCheck on Average Directional Index for Rigel Pharmaceuticals Inc. (RIGL) - Sherwood Daily (NASDAQ:RIGL)
sherwooddaily.com - January 18 at 8:09 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Wall Street Beacon (NASDAQ:RIGL)
wsbeacon.com - January 18 at 8:08 AM
News IconKnuckling Down on Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - January 18 at 8:08 AM
News IconStock Momentum Skidding to a Halt For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Wall Street Beacon (NASDAQ:RIGL)
wsbeacon.com - January 18 at 8:08 AM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - January 16 at 6:43 PM
finance.yahoo.com logoRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:RIGL)
finance.yahoo.com - January 16 at 1:41 PM
realistinvestor.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EPS Estimate At $-0.02 - RealistInvestor.com (NASDAQ:RIGL)
www.realistinvestor.com - January 14 at 5:46 AM
News IconRigel Pharmaceuticals Inc RIGL Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RIGL)
www.bioportfolio.com - January 9 at 8:15 AM
prnewswire.com logoRigel Provides Business Updates and Preliminary Data in IgA Nephropathy - PR Newswire (press release) (NASDAQ:RIGL)
www.prnewswire.com - January 7 at 1:42 AM
finance.yahoo.com logo7:32 am Rigel Pharma announces co expects to end 2016 with approx $74.8 mln in cash, cash equivalents, and short-term investments; believes this will be sufficient to fund its operations into 2018 (NASDAQ:RIGL)
finance.yahoo.com - January 6 at 3:06 AM
publicnow.com logoRigel Provides Business Updates and Preliminary Data in IgA Nephropathy (NASDAQ:RIGL)
www.publicnow.com - January 6 at 3:06 AM
realistinvestor.com logoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EPS Estimaged At $-0.02 - RealistInvestor.com (NASDAQ:RIGL)
www.realistinvestor.com - December 31 at 12:52 AM
News IconAre the Technicals Adding up for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - December 31 at 12:52 AM
News IconIs This Equity Ready for a Breakout: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - December 30 at 8:42 AM
News IconCan This Stock Make a Ripple in the Market: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - December 29 at 8:47 AM
News IconStock in the Limelight: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - December 28 at 6:17 AM
News IconNotable Stock For Under $5: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Prospect Journal (NASDAQ:RIGL)
prospectjournal.com - December 20 at 2:11 PM
News IconFollowing the Numbers for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Liberty News (NASDAQ:RIGL)
libertynewsrecord.com - December 20 at 2:11 PM
News IconStock Review for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Liberty News (NASDAQ:RIGL)
libertynewsrecord.com - December 19 at 8:05 AM
insidermonkey.com logoIs Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio? (NASDAQ:RIGL)
www.insidermonkey.com - December 14 at 9:42 PM
News IconMarket Focus: Watching Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - OIB News (NASDAQ:RIGL)
oibnews.com - December 14 at 8:00 AM
News IconTechnical Buzz on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - The Business Journal (NASDAQ:RIGL)
belmontbusinessjournal.com - December 13 at 12:40 AM
News IconROIC Watch for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Liberty News (NASDAQ:RIGL)
libertynewsrecord.com - December 13 at 12:40 AM
News IconInside the Numbers on Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Liberty News (NASDAQ:RIGL)
libertynewsrecord.com - December 10 at 12:29 AM
seekingalpha.com logoAclaris launches early-stage study of ATI-50001 in hair loss disorder (NASDAQ:RIGL)
seekingalpha.com - December 8 at 8:54 AM
News IconTechnical Reports on Generic Drugs Stocks -- Zoetis, Rigel Pharma, Mallinckrodt, and Diplomat Pharmacy (NASDAQ:RIGL)
www.kait8.com - December 7 at 8:56 AM

Social

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Where is Rigel Pharmaceuticals' stock going? Where will Rigel Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $6.20 in the next twelve months.

When will Rigel Pharmaceuticals announce their earnings?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

  • BMO Capital Markets analysts commented, "We believe follow-up data from the fostamatinib Phase III program further supports Rigel's decision to move forward with the NDA filing, and our belief that the addressable population will be greater than the 18% stable response rate seen in the pivotal studies. We believe reaching an FDA Adcom would be a positive event, as we believe a panel of clinicians would likely favor approval." (1/30/2017)
  • Jefferies Group LLC analysts commented, "Despite mixed fosta Ph3 data in ITP, RIGL is on track to file an IND in 1Q17 based on its discussion with its regulatory consultant & no FDA objection to date. Key catalysts include: (1) FDA decision on acceptance of fosta NDA by ~May 2017, & (2) AdComm outcome (if NDA accepted) in ~Sept./Oct." (1/11/2017)

  • According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (12/31/2016)

  • Piper Jaffray Companies analysts commented, "Celsion announced that the independent Data Safety Monitoring Board (DSMB) has reviewed the data from the first three cohorts (N=9) of patients treated with GEN-1 (DNA-based IL-12) in the phase Ib Ovation study (ovarian cancer) and recommended that the study proceed to treating the fourth and final cohort." (9/15/2016)

Who owns Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Palo Alto Investors LLC (4.22%), Patrick Lee, MD (4.22%), State Street Corp (1.73%), Dimensional Fund Advisors LP (1.20%) and J. Goldman & Co LP (0.79%).

Who sold Rigel Pharmaceuticals stock? Who is selling Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Dimensional Fund Advisors LP, Two Sigma Investments LP, Marshall Wace LLP, First Republic Investment Management Inc. and Metropolitan Life Insurance Co. NY.

Who bought Rigel Pharmaceuticals stock? Who is buying Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Paulson & CO. Inc., Russell Investments Group Ltd., State Street Corp and J. Goldman & Co LP.

How do I buy Rigel Pharmaceuticals stock?

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rigel Pharmaceuticals stock cost?

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.30.

Rigel Pharmaceuticals (NASDAQ:RIGL) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Earnings History Chart

Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Dividend History Chart

Dividend Payments by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Last Updated on 2/26/2017 by MarketBeat.com Staff